Pfizer Manufacturing Austria is Pfizer’s production site at Orth an der Donau. The plant meets global demand for vaccines to protect against tickborne encephalitis and meningitis caused by serogroup C meningococci.
Proxygen harnesses the cellular protein quality control system to develop therapies against cancer and other life-threatening diseases. We are focused on particular small molecules called “molecular glue degraders” which mediate recruitment of a disease-causing protein to a ubiquitin ligase where it is ubiquitinated and directed to the proteasome for degradation. Hence, instead of merely blocking the function of harmful proteins, molecular glue degraders enable their complete and selective elimi
APEIRON Biologics AG at a glance: APEIRON Biologics is a privately held European biotech company based in Vienna, Austria, focused on the discovery and development of treatments for respiratory diseases and novel cancer immunotherapies. APEIRON Biologics´ projects and technologies are based on a strong patent portfolio and partnerships with leading pharmaceutical companies and academic institutions.
a:head aims to develop new therapeutics for the treatment of brain disorders based on human cerebral organoids
Origimm (‘Origins of immunity’) is a biotech company that specializes in the discovery of antigens and dermatological drug targets. The company uses its proprietary technology that employs reverse functional screening to discover and develop breakthrough therapies for the prevention and treatment of skin microbiome-associated diseases such as acne vulgaris and other microbiome-associated infections.
What if we could give the body instructions to produce its own drugs? This would be nothing less than a new era in drug therapy and is exactly what messenger RNA (mRNA) could achieve. At ACCANIS, we develop innovative therapeutics for the treatment of common, localized diseases using mRNA. Each cell in your body uses mRNA to translate genetic information into proteins. ACCANIS´ innovative technology takes advantage of this natural mechanism in order to enable effective, on-demand therapeutics.
Solgate is a new research-driven biopharmaceutical startup that develops drugs targeting solute carrier (SLC) proteins, the largest family of membrane transporters. By modulating the function of the “gates” to cellular metabolism, Solgate aims to address unmet medical needs in neurological diseases, in metabolic disorders and in cancer. Solgate is located in the newly established IST Park, a space housing a growing community of technology startups and biotech companies, adjacent to IST Austria.
CYPRUMED GmbH, is an Austrian drug delivery company developing enabling technologies for the non-invasive delivery of biologics, with a focus on oral peptide delivery. Key activities include formulation research, IP protection and technology out-licensing.
VALIDOGEN, formerly known as VTU Technology, is a leading Austrian contract research and development company. VALIDOGEN offers UNLOCK PICHIA - the broadest toolbox and most versatile technology platform available for Pichia pastoris recombinant protein production. Founded in 2008, the company emerged to a globally recognized player in the field of Pichia pastoris based protein expression. VALIDOGEN has established a broad range of tools and know-how for the generation of high-performance Pichia processes. Exclusive proprietary technologies and profound experience of the VALIDOGEN team lead to competitive production processes for a wide range of recombinant proteins. Headquartered in Raaba-Grambach, near Graz, Austria, VALIDOGEN is a private company and independent subsidiary of the KonValue Holding GmbH.
Bio-ferm is active in R
Vivaldi Biosciences is developing its DeltaFLU influenza vaccine to provide broad cross-protection and superior efficacy in the prophylaxis of seasonal and pandemic influenza. DeltaFLU is composed of influenza vaccine strains genetically modified by deletion of the gene for nonstructural protein 1.
Planta was founded in 1994 by three dynamic biotechnologists whose aim was to put their ideas and visions into practice. Today Planta is an innovative drug development company. Our staff members’ academic backgrounds lie in the fields of biochemistry, biology, pharmacology and toxicology. Our permanent key personal consists of seven co-workers – a group which allows for a compact and familiar atmosphere. Flexibility is our strength and is a great asset to our customers and cooperation partners.
BlueSky Immunotherapies GmbH (Ltd.) is a clinical-stage biotech company. The company’s business is based on its own proprietary, novel technology platform for interferon-inducing viral vectors (delNS). Interferons have immunostimulatory and antiviral properties. BlueSky uses these delNS- mediated properties for therapies against cancer and viral infectious diseases.